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Protein-protein interactions (PPIs) dominate all cellular functions across every domain of life. If 
PPIs become aberrant, they may result in many human diseases, such as cancer or Alzheimer’s. Despite 
their clinical significance, modulating aberrant PPIs is a daunting task. Most PPI surfaces are long, 
hydrophilic and structurally complex. Thus, finding molecules that moderate specific aberrant PPIs is an 
important goal in drug discovery research. For example, PPIs have been modulated by peptidomimetics, 
synthetic peptides that assume three-dimensional structures similar to proteins, but unlike natural peptides, 
they are proteolytically stable. However, building libraries of peptidomimetics is challenging as current 
methods rely on solid phase peptide synthesis, which limits the size and diversity of peptidomimetic 
libraries. As such, using the translation machinery to synthesize peptidomimetics is an attractive approach. 
In Chapter 1, we begin by discussing bacterial protein synthesis. Then, we delve into a detailed 
discussion of the application of the bacterial translation machinery for the in vitro translation of synthetic 
peptides. In this discussion, we review the different technologies, their advantages and limitations with 
respect to the incorporation of amino acids with unnatural backbones.  
After reviewing the methods used to incorporate backbone analogs, and their compatibility with the 
bacterial translation machinery, we describe a novel approach for the ribosomal incorporation of β-amino 
acids analogs containing an α-substituent, α-hydroxy-β-amino acids (Chapter 2). We demonstrate that the 
ribosome incorporates this new class of substrates through the formation of an intermediate ester bond that 
rapidly rearranges to form a native peptide bond. Using this approach, we show that α-hydroxy-β-amino 
acid single incorporation efficiencies are comparable the incorporation efficiencies obtained with natural 
amino acids.  
In Chapter 3, we apply this approach to the synthesis of peptides containing multiple α-hydroxy-β-
amino acids. This chapter describes the results obtained with the in vitro synthesis of peptides containing 
two consecutive α-hydroxy-β-amino acids, three consecutive α-hydroxy-β-amino acids, and alternating α-
hydroxy-β-amino acids and α-amino acids. Based on these results, we propose experiments to improve 
	
these incorporation yields for the application of this technology for the in vitro synthesis of diverse 
peptidomimetic libraries. 
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1 Chapter 1 Introduction 
Protein-Protein Interactions (PPIs) are present in all domains of life 
Protein-protein interactions (PPIs) are deliberate stable or transient interactions between two 
proteins that regulate many essential cellular processes in all domains of life. Decades of structural, 
biochemical, genetic and computational studies have revealed that PPIs are intimately linked to protein 
structure, which is a result of their ability to assemble to form primary, secondary, tertiary and quaternary 
structures.1–3 Proteins are composed of a defined amino acid sequence connected by amide bonds. These 
amide bonds interact with each other to form stable secondary structures such as β-sheets and α-helices. 
Secondary structures encourage amino acid side-chains to interact with each other via non-covalent 
interactions, allowing proteins to adopt the three-dimensional structures that confer unique functions and 
enables specific PPIs. In some cases, proteins interact with each other to form multi-subunit complexes. 
Electrostatic interactions, hydrogen bonds, and hydrophobic interactions between subunits determine the 
quaternary structure of multi-subunit complexes. By studying protein structure and the role that protein 
structure plays in PPIs, we can begin to elucidate how specific PPIs regulate the fundamental intra- and 
extra-cellular processes that govern the growth and the fate of cells.4 Among other things, PPIs may 
influence biological processes by promoting the activity of other proteins, by inactivating other proteins, and 
by changing the substrate specificity of a protein.5 Notably, the deregulation of PPIs caused by mutations 
in the genes that encode proteins is frequently associated with abnormal phenotypes. In humans, abnormal 
phenotypes manifest as cancers, neurological diseases such as Parkinson’s or Alzheimer’s, and facile 
propagation of viral proteins by host cells. 6–13 Understanding the structural basis of PPIs that are implicated 
in human diseases will ultimately guide efforts to design drugs to target them. 
 
Structural Features of PPIs 
Structural studies are essential for drug discovery efforts because they facilitate the engineering of synthetic 
molecules that specifically target aberrant PPIs. Structural studies have shown that PPI interfaces feature 
large flat surfaces ranging from 1000-2000Å in length, and include complementary geometries between the 
proteins involved, hydrophobic cores, hydrophilic bridges, hydrogen (H)-bonds and electrostatic 
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interactions.4 Consequently, most PPIs were deemed ‘undruggable’ because they lacked small 
hydrophobic pockets where small molecules can bind.14 Once site-directed mutagenesis experiments 
revealed that small hydrophobic ‘hot spots’ have high contributions to the binding energy of PPIs,15–18 
computational advances as well as several methods for discovering small molecule inhibitors of PPIs, 
including fragment screening and molecular design, emerged.19,20 In spite of these technological advances, 
PPI ligands are proteins and, as such, one would expect inhibitors to structurally resemble their targets. 
Natural peptides that mimic the surfaces of target proteins have been used to inhibit PPIs, i.e. the p53·hDM2 
interaction, which is implicated in abnormal cell growth and replication, leading to tumors.21 Natural peptides 
are attractive, potential PPI inhibitors large libraries of these peptides can be synthesized in vitro quickly 
and efficiently using the translation machinery (TM) in conjunction with in vitro display methods.22 While 
effective, peptides with natural backbones are highly susceptible to proteolysis and do not retain their 
secondary structures in solution.23 One way to address this problem is by using peptidomimetics, or 
synthetic peptides that mimic protein surfaces.24 Peptidomimetics can be natural peptides that have been 
cyclized after in vitro synthesis,25 or peptides with synthetic backbones (Figure 1.1).  
 
Figure 1.1 Types of Peptidomimetics 
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Modifications to the peptide backbones confer increased proteolytic stability as well as higher binding 
affinities for their target protein. Ideally, we large libraries of peptidomimetics would be synthesized using 
the TM. Unfortunately, the limited number and type of monomers that the ribosome can use greatly limits 
the structural diversity of these libraries. Hence, developing new technologies for the synthesis of unnatural 
peptides represents an important goal. In this chapter, I will give a brief overview of the TM with an emphasis 
on how our understanding of the TM has facilitated the development of technologies for synthesizing 
synthetic polypeptides with unnatural backbones.  
 
The translation machinery (TM) 
The synthesis of proteins by the TM requires that the genetic information stored in the form of DNA 
is first transcribed into an intermediate messenger RNA (mRNA) template. Subsequently, the mRNA 
templates are decoded by the TM and translated into proteins Translating mRNA into protein depends on 
the genetic code, which specifies the set of three nucleotides, or codons, that correspond to a particular 
amino acid.26 Since each codon is a triplet and there are four nucleotides, the genetic code contains 64 
distinct codons (43 codons). Out of the 64 codons, 61 correspond to one of the 20 canonical amino acids.  
An important step towards achieving accurate translation is the aminoacylation, or “charging” of the 
transfer RNA (tRNA) substrates that carry the amino acids to the ribosome, with their cognate amino acids. 
Each tRNA carries one amino acid, but one amino acid may be charged onto more than one tRNA; tRNA 
variants that carry the same amino acid are called isoacceptors.27 
While tRNAs have varied primary structures, the tRNAs have a defined secondary and tertiary 
structure that help maintain the accuracy and fidelity of translation. The secondary structures of tRNAs is 
known as the cloverleaf model. The cloverleaf model arises from the stems that form at the portions of the 
primary sequence that are complementary, and the loops that form at the portions that lack complementary 
sequences.28,29  It states that every tRNA contains 3 stem-loops: dihydrouridine stem-loop or D-arm 
(contains two modified bases, hydrouridine), TΨC stem-loop (contains one modified base, pseudouridine) 
and the anticodon stem-loop (AC-arm). They also have an acceptor stem, which is formed by the interaction 
between the 5’ and 3’ ends of the tRNA, and the variable loop, a small sequence that varies in length among 
different tRNAs. tRNAs also adopt a well-defined tertiary structure that resembles the letter L.30,31  The L-
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shape is due to base stacking that brings the D- and TΨC arms one on top of the other, and forces the 
acceptor stem and anticodon stem-loop to be in the opposite ends of the tRNA. Amino acids are esterified 
to the acceptor stem, while the anticodon dictates which amino acid is incorporated into a polypeptide chain 
in response to a codon.  
The central component of the TM is the ribosome, a universally conserved macromolecular 
machine composed of two subunits that together form binding sites for the aa-tRNA substrates, the A-site, 
the P-site, and the E-site. In bacteria, the two subunits are the large, or 50S, subunit and the small, or 30S 
subunit. Each subunit is made of a ribosomal RNA (rRNA) backbone and a subset of ribosomal proteins 
that interact with the rRNA to stabilize its correct folded structure. In addition, the TM also includes the 
translation factors, which interact with the ribosome to ensure that protein synthesis proceeds with high 
efficiency, speed, and fidelity.  
Translation occurs in three major steps termed the initiation, elongation and termination steps. The 
initiation step is facilitated by initiation factors (IF1, IF2 and IF3); the elongation step is facilitated by 
elongation factors (EF-Tu, EF-Ts and EF-G); and, the termination step is facilitated by release factors (RF1, 
RF2 and RF3). In this chapter, I will focus my discussion on the elongation step, as it is arguably the most 
important step for (UAA) amino acid incorporation.  
During translation initiation, an elongation-competent 70S ribosomal complex is formed that 
contains the mRNA start codon and the initiator tRNA in the P site, and an empty A site. Elongation is a 
cyclical process that involves three main steps: aa-tRNA selection, peptide bond formation, and 
translocation. Below, I discuss these three steps of the elongation cycle in more detail.  
 
Initial aminoacyl-tRNA selection and proofreading ensures translation fidelity 
Initial selection happens when the EF-Tu:GTP:aa-tRNA ternary complex (TC), delivers the aa-tRNA 
to the ribosomal A site.32  Initially, the aa-tRNA is bound in the so-called A/T hybrid state. In the A/T state, 
the aa-tRNA anticodon stem loop (ASL) is bound to the A site while the aa-tRNA acceptor stem remains 
bound to EF-Tu. 33,34 In the A/T hybrid state, the ribosome quickly screens the nature of the codon:anticodon 
interaction.35,36 During this initial selection, if the codon:anticodon interaction is non-cognate (i.e. there are 
not complementary base pairs), the ternary complex falls off. During proofreading, the codon:anticodon 
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interaction is interrogated a second time. If the codon:anticodon interaction is near-cognate (i.e. the first or 
second position of the codon: anticodon interaction is not able to base pair, but the other two bases are 
cognate), then the ternary complex falls off. 37  If the aa-tRNA is cognate, that is to say that the 
codon:anticodon interaction results in three complementary base pairs or two complementary base pairs 
with a wobble pair in the third position, a series of rearrangements within the 50S are triggered by the 
codon:anticodon interaction.33  GTP is hydrolyzed and EF-TU:GDP dissociates from the ribosome, and the 
aa-tRNA acceptor stem accommodates into the A site.38  This elongation complex is now ready to 
participate in peptide bond formation. This process is visualized in Figure 1.2. 
 
Figure 1.2 Elongation Cycle - Initial Selection and Proofreading 
Peptide bond formation  
The peptidyl transferase center (PTC) is located on the 50S subunit and it is responsible for 
catalyzing peptide bond formation (polymerization of amino acids into polypeptides). During peptide bond 
formation, the nucleophilic α-amine of the aa-tRNA in the A site attacks the carbonyl carbon of the peptidyl-
tRNA in the P site, resulting in the formation of a tetrahedral intermediate. The tetrahedral intermediate then 
collapses yielding an amide bond that extends the peptide by a one amino acid, and transfers the peptide 
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chain to the A-site tRNA. Hence, during peptide bond formation, the P-site peptidyl-tRNA serves as the 
“peptide chain donor”, and the A-site aa-tRNA serves as the “peptide chain acceptor” Figure 1.3.   
 
Figure 1.3 Peptidyl Transfer Reaction 
Structural and biochemical studies elucidated the PTC’s mechanism of action. Fragment reactions 
where small molecules that mimic aa-tRNAs, such as puromycin and puromycin analogs, react with the P-
site substrate demonstrated that ribosome’s catalytic activity is located on the 50S subunit. 39,40  Moreover, 
while the 50S subunit is composed of rRNA and ribosomal proteins, ribosomal proteins do not play a 
significant role in peptide bond formation.41 When the first high-resolution crystal structure of the 50S 
subunit complexed to two aa-tRNA substrate analogs it shows that there are no proteins near the site on 
the PTC where the nucleophilic attack occurs. Therefore, the ribosome’s catalytic activity is exclusively 
derived from rRNA, making the ribosome a ribozyme. 42,43  Further biochemical studies where the rates of 
tRNA accommodation was examined as a function of pH confirmed the PTC catalyzed peptide bond 
formation is pH independent suggesting that the ribosome catalyzes peptide bond formation by lowering 




 Translocation, the process in which the mRNA and the A-site and P-site tRNAs are shifted 
upstream to reveal a new codon in the A site, is catalyzed by EF-G. During elongation the ribosome 
oscillates between two states that are dictated by the position of the tRNA substrates. In the pre-
translocation state (PRE), the peptidyl tRNA is bound to the A site and the deacylated tRNA is bound to the 
P site. In contrast, in the post-translocation state (POST), the peptidyl tRNA is bound to the P site and the 
deacylated tRNA is bound to the E site.46,47 Interestingly, in the absence of EF-G:GTP, PRE-state ribosomal 
complexes have been shown to stochastically fluctuate between two global states (GSI and GSII).34,48,49 In 
the first global state, the subunits are in the non-rotated conformation, the tRNAs are in the classical A/A 
and P/P configurations, and theL1 stalk is in the open conformation. In the second global state the small 
subunit platform rotates with respect to the large subunit, the L1 stalk adopts a closed conformation, and 
the peptidyl-tRNA in the A site and the deacylated tRNA in the P site are in hybrid A/P and P/E states, 
respectively. In these hybrid states, the ASLs of both tRNAs remain static on the small subunit, while the 
acceptor ends spontaneously move to the E site and the P site. 49,50 In the presence of EF-G:GTP, GSII is 
favored, which ultimately results in movement of the ASLs of the P/E and the A/P hybrid tRNAs to the E 
and P sites (Figure 1.4).49 
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Figure 1.4 Translocation 
Synthesizing genetically encoded unnatural peptides 
Early research exploring the mechanism of mRNA translation by the ribosome led to the 
identification of the key co-factors and substrates of the translation pathway. The use of cell-free extracts 
as in vitro translation systems, first reported in 1958, demonstrated the importance of ATP and GTP. Cell-
free translation extracts were also instrumental in the identification of the aa-tRNAs, then referred to as 
soluble RNAs (sRNAs), which were hypothesized to serve as the adaptor molecule during protein 
synthesis.51  The adaptor hypothesis proposed that the tRNA adaptor molecules were the link between the 
genetic information and the amino acids incorporated by the ribosome, and suggested that the ribosome 
was oblivious to the identity of the amino acid on the tRNA.52  Yet, testing the validity of the adaptor 
hypothesis required more control over the cell-free translation systems. Gaining control over the cell-free 
translation systems was achieved by incorporating synthetic mRNAs and chemically modified aa-tRNAs 
into the cell-free translation extracts.53–56  The results of early studies using these cell-free translation 
extracts seemed to confirm the adaptor hypothesis. Indeed, it was observed that the codon:anticodon 
interaction directed the incorporation of amino acids, not the identity of the amino acid.57 As such, this 
approach of chemically modifying aa-tRNAs for obtaining misacylated tRNAs opened the door to the 
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mRNA-directed natural amino acid misincorporation,58 and incorporation of amino acids with modified side 
chains, and backbones. 59–62  
Meanwhile, cell-free extracts were also used to elucidate the mechanism of action of puromycin, 
an antibiotic derived from the bacterium, Streptomyces alboniger39 that resembles the 3’ end of aa-tRNAs 
and reacts with the peptidyl tRNA to inhibit in vivo and in vitro protein synthesis.63,64 Because puromycin’s 
amino acid moiety is linked to the nucleoside via an amide bond instead of an ester bond, it cannot be 
elongated and therefore, arrests translation. The ease of changing puromycin’s aminoacyl moiety, 
compared to misacylating aa-tRNAs, along with the ease of setting up puromycin analog assays paved the 
way for the first studies of the plasticity of the ribosomal PTC for different amino acid backbone analogs. 
40,65  
The first examples of using both chemically modified aa-tRNAs and puromycin analogs to study 
the ribosome’s substrate specificity were presented by Rich and Fahnestock. Using the initiator N-formyl-
methionyl-tRNAfMet (fMet-tRNAfMet) as the P-site substrate and α-hydroxy puromycin as the A-site substrate, 
they showed that the ribosome catalyzes ester bond formation nearly as efficient as it catalyzes amide bond 
formation.66 Later, they expanded on this result by showing that the ribosome is also capable of 
polymerizing deaminated phenylalanyl-tRNAPhe (Phe-lac-tRNAPhe) in response to a synthetic poly(U) 
message.62 In addition, they showed that the ribosome is capable of site-specifically introducing deaminated 
alanyl-tRNAAla (lac-tRNAAla) or Phelac-tRNAPhe into the second or fifth position, respectively, of a natural 
mRNA encoding a hexapeptide fragment (fMet-Ala-Ser-Asn-Phe-Thr) of the viral coat protein R17 in vitro.67  
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Figure 1.5 Ribosome-catalyzed ester formation62, 67 
Subsequently, they showed that the co-incubation of thio-puromycin and N-acetyl-[3H]-Phe-tRNAPhe into 
cell-free translation extracts yielded a thioester, the identity of which was confirmed by co-migrating 
chemically synthesized authentic markers with the thioester translation product.68 Translation reactions 
where the P-site puromycin analogs included either a thioester or a phosphinoester, suggest that the 
ribosome will accept heteroatoms in the P-site substrate. 69,70 However, it is not clear whether it will accept 
other heteroatom nucleophiles, other than NH2, OH, and potentially SH.  
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Figure 1.6 Ribosome-catalyzed ester and thioester formation66,68 
Evolution of techniques for misacylating tRNAs 
In nature, tRNAs are charged by aminoacyl synthetases (aaRSs). AaRSs are multi-domain 
enzymes that charge tRNAs, in a two-step reaction. In the first step, aaRSs bind and activate an amino acid 
using ATP as the energy source. The activation of the amino acid occurs when the amino acid carboxylate 
attacks the α-phosphate of the aaRS-bound ATP, resulting in the release of inorganic pyrophosphate and 
the formation of a high-energy aminoacyl adenylate (aa-AMP):aaRS complex. In the second step, the aa-
AMP:aaRS complex binds to its cognate tRNA and catalyzes the esterification of the amino acid to either 
the 2’-hydroxyl or the 3’-hydroxyl of the terminal 3’-adenine (A76) of the tRNA.  
The ability of aaRSs to both discriminate between different amino acids and to identify their cognate 
tRNAs is crucial for the accuracy of translation. It has been previously shown that in the absence of the 
isoleucyl-tRNA (tRNAIle), the Ile-aaRS can bind and activate valine (Val), forming an non-cognate Val-
AMP:Ile-aaRS complex.71  However, in the presence of tRNAIle, Ile-aaRS hydrolyzes Val-AMP rather than 
misacylting tRNAIle. In addition, if tRNAIle is chemically misacylated with Val (Val-tRNAIle) and incubated 
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with Ile-aaRS, the Val-tRNAIle is readily deacylated.72 These results reveal that aaRSs use pre-transfer and 
post-transfer editing mechanisms to ensure that tRNAs are charged with their cognate amino acids. 
Because of the high accuracy exhibited by aaRSs, chemical strategies were developed to misacylate tRNAs 
with various natural and unnatural amino acids.73  
The chemical aminoacylation of tRNAs provided a universal platform to study the plasticity of the 
peptidyl transferase center of the ribosome using full-length, misacylated tRNAs. These studies, in turn, led 
to the development of new technologies for the ribosomal synthesis of peptides with unnatural backbones 
(discussed below). The first chemical synthesis of tRNAs harboring UAAs was reported by the Hecht group. 
Hecht and co-workers demonstrated that tRNAs could be misacylated with N-acetyl-UAAs, and that these 
UAAs were viable substrates for the ribosome. Using a standard ribosomal dipeptide formation assay.74–76 
they measured the ability of several misacylated tRNAPhe variants including N-acetyl-D-Phe-tRNAPhe, N-
acetyl-DL-β-Phe-tRNAPhe, and N-acetyl-D-Tyrosine (Tyr)-tRNAPhe to function as peptide chain donors. Their 
results revealed that N-acetyl-DL-β-Phe exhibits remarkable donor activity, while N-acetyl-D-amino acids 
(D-aa’s) do not, consistent with previous D-aa incorporation studies, where D-Tyr-tRNATyr was charged by 
the natural Tyr-RS and incorporated into peptides using cell-free translation systems despite their low 
affinity for EF-Tu. 77,78  While these experiments represented the first time the structural plasticity of the PTC 
of the ribosome was probed, their use of UAA-tRNAs with blocked amines prevented them from studying 
the effect of these UAAs on binding of EF-Tu, binding to the ribosomal A site, and on their ability to act as 
peptide chain acceptors.  
Further optimization of the synthetic approach for obtaining chemically misacylated tRNAs by 
various research groups expanded the application of chemical approaches to misacylate tRNAs. These 
new approaches made it possible to misacylate tRNAs with any free amino acids in high yields (~30-50% 
aminoacylation efficiency),79,80 thereby permitting an investigation of the ability of D- and β-aminoacyl 
tRNAs to bind the A site and act at peptide chain acceptors. For example, protecting the α-amine of amino 
acids with an enzymatically cleavable protecting group afforded the first synthesis of D-Phe-tRNAPhe, D-
Tyr-tRNAPhe and D,L-β-Phe-tRNAPhe with free were α-amines.81 Using the dipeptide formation assay, the 
acceptor ability of D-Phe-tRNAPhe, D-Tyr-tRNAPhe and D,L-β-Phe-tRNAPhe was tested. Each UAA-tRNA was 
added independently to mRNA-programmed ribosomes containing N-acetyl-Phe-tRNAPhe in the P-site 
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While D,L-β-Phe-tRNAPhe  is a good peptide chain donor, the results indicated that it is a poor peptide chain 
acceptor. D-aas were not incorporated.  
 
Cell-Free Translation Assays and Nonsense Suppression 
The development of a general method to misacylate tRNAs with UAAs led the Schultz lab to 
develop a strategy to site-specifically incorporate UAAs into proteins by mutating sense codons to the 
amber (TAG) stop codon.82  
 
Figure 1.7 Site-directed mutagenesis 
This method was used to synthesize variants of the T4 lysozyme (T4L) harboring UAAs to determine how 
these UAAs affect its stability.83  Using a cell-free translation extract they investigated the ribosome’s ability 
to incorporate cyclic and linear N-alkyl amino acids, α,α-disubstituted amino acids, α-hydroxy acids, D-
amino acids and β-amino acids. Cyclic, linear N-alkyl amino acids and α,α-disubstituted amino acids are 
incorporated with suppression efficiencies ranging from 23-46%, while α-hydroxy acids are incorporated 
with a 30% suppression efficiency.83 (Figure 1.8) 
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Figure 1.8 Backbone Analogs incorporated by site-directed mutagenesis 
On the other hand, no suppression was observed when either D- or  β-amino acids were used. Substituting 
natural amino acids with N-alkyl amino acids and α,α-disubstituted amino acids resulted in proteins with 
similar or slightly higher thermal stabilities.  
The Chamberlain group developed a rapid assay to study the ability of UAAs to function as a 
peptide chain donor and as a peptide chain acceptor.84,85 They misacylated a suppressor tRNA with UAAs 
and included them in their rapid assay.  
 
Figure 1.9 Rapid assay for stop codon read-through84,85 
The rapid assay involves using an mRNA that codes for a 16-mer polypeptide encoding a stop codon in the 
ninth position. Successful stop codon suppression leads to the 16-mer polypeptide product, while 
unsuccessful suppression leads to a truncated 8-mer product. With this assay, they found that N-methyl-
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Phe and α-hydroxy-Phe were incorporated but β-Phe-tRNACUA and D-Phe-tRNACUA were not. While these 
results are consistent with previous reports,74,81 the authors never confirmed that the correct amino acid 
was being incorporated.  
Cell-free translation extracts have also been used to study the ribosome’s ability to synthesize 
dipeptides with altered connectivities.86  To obtain peptides with an altered connectivity, N-chloroacetyl-
Phe-tRNAPhe was used as the P-site substrate. N-chloroacetyl-Phe-tRNAPhe has two electrophilic carbons, 
as opposed to natural aa-tRNAs, which only have one – the carbonyl carbon. The A-site α-amine can react 
with the carbonyl carbon to give the expected dipeptide product or, alternatively, it could react with the N-
chloroacetyl carbon, yielding a dipeptide with an altered connectivity.  
 
Figure 1.10 Ribosomal synthesis of peptides with altered connectivities86 
Another way in which the peptide connectivity can be altered is by replacing the A-site aa-tRNA 
containing a natural amino acid with hydrazinophenylalanine-tRNA, which contains two nucleophiles, the 
α-amine and the β-amine.87  
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Figure 1.11 Dipeptide Formation with hydrazinophenylalanine87 
Using a dipeptide assay, they showed that both the α-amine and the β-amine can act as nucleophiles as 
shown by the 71% dipeptide yield (Figure 1.11). HPLC analysis of the translation products indicated that 
the β-amine might be more reactive than the α-amine, as demonstrated by the ratios of 1:1.2 for α-amine 
product to β-amine product. Furthermore, when they incorporated this UAA into E. coli Dihydrofolate 
reductase (DHFR) using suppressor tRNACUA, they observed 9-15% stop codon read-through. These 
results are particularly interesting when you consider that β-amino acids do not seem to be compatible with 
the TM. It could be that the additional hydrogen bond donor on hydrazinophenylalanine enables this β-
amino acid analog adopt a more stable configuration in the PTC when compared to β-amino acids with 
carbon backbones. The incorporation of hydrazinophenylalanine is further confirmed when they studied the 
ability of the suppressor tRNACUA charged with (aminooxy)acetic acid and incorporated it into E. coli 
DHFR.88  While they observed a low suppression activity (10%), their results seem to indicate that when 
part of the β-amino acid backbone is replaced with heteroatoms (N or O), incorporation of β-amino acid 
analogs is possible, providing a possible way to incorporate β-aa-tRNAs. Amber suppression in cell-free 
translation extracts have shown that β-hydroxy acids are also incorporated preferentially over β-amino 
acids, presumably, because β-hydroxy acids do not require deprotonation prior to peptide bond formation.89  
Even though natural amino acid polymerization by the ribosomal PTC is not pH dependent,44 it is possible 
that the incorporation of β-amino acids is pH dependent. Indeed, the pKas of β-amino acids are higher than 
the pKas of natural amino acids; therefore, deprotonation could be rate-limiting step in β-amino acid 
incorporation. Another possibility is that compared to β-aa-tRNAs, β-OH-tRNAs may have a higher affinity 
for EF-Tu and the ribosomal A site. Collectively, based on the incorporation of backbone analogs reviewed 
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thus far, it appears that the carbon backbone analogs are incompatible with the TM, while amino acids with 
heteroatomic backbones are compatible with the TM.  
Although significant strides were made in studying the plasticity of the ribosomal PTC for various 
UAA-tRNA substrates in cell-free translation extracts, there are drawbacks that limit their use. For instance, 
the protein yields from cell-free translation extracts were low, presumably due to competition between 
suppressor tRNAs and RFs. In addition, UAA mutagenesis requires stop codons, but the genetic code only 
has three stop codons limiting the incorporation of UAAs to two. Finally, synthesizing UAA-tRNAs using the 
chemical approach is difficult and time-consuming. These drawbacks served as a driving force for the 
development of a customizable reconstituted cell-free assay that improved the nature of the assays being 
implemented and introduced a new way to charge tRNAs with natural and UAAs.  
 
Reconstituted Cell-Free Translation Systems and Sense Codon Reassignment 
In 2001, the Ueda group reported the first customizable translation system, the Protein Synthesis 
Using Recombinant Elements, PURE system.90  
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Figure 1.12 PURE Assay90 
The PURE system consists of purifying the translation components, including all the essential translation 
factors (IF1, IF2, IF3, EF-Tu, EF-G and EF-Ts), tRNAs, RFs, aaRS, natural amino acids, and RRFs, from 
E. coli, and it can be used to translate five different proteins and peptides with high yields and activities. 
Furthermore, they were able to incorporate misacylated Val-tRNAsupp efficiently in response to the amber 
stop codon by removing RF1. The PURE assay has several advantages over crude cell-free translation 
extracts for protein synthesis. To start, they allow complete control over all the components added to the 
reactions, which increases yields of both proteins containing natural and UAAs that are incorporated by 
stop codon suppression. Also, the PURE system does not have proteases or nucleases present, so proteins 
are stable, mRNAs are not degraded, and nucleotides are consumed only when translation occurs, making 
energy consumption efficient which results in high protein yields.90  
The ability to exclude certain aaRS, facilitated the application of mRNA display, an approach 
developed to build peptide-mimetic libraries,91 by sense codon reassignment. N-methyl amino acids, 
dehydroalanine, and α-amino acids with unnatural side chains were obtained by either chemically modifying 
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aa-tRNAs before adding them to the reaction, modifying the amino acid side chains and backbones, 
including cyclizing peptides, post-translationally, or generating misacylated aa-tRNAs in situ.61,92–94 While 
the PURE system has proven to be a valuable toolkit for scientists, the fact remains that applying the PURE 
system for unnatural amino acid incorporation requires purifying all of the components which is time-
consuming, and the presence of RFs and aaRS complicates the reassignment of multiple sense codons to 
UAAs. This, in turn, affects the synthesis of diverse peptide libraries.  
An alternative approach to the PURE assay was developed by the Cornish lab, which involves the 
purification of essential translation components, such as ribosomes, mRNAs, aa-tRNAs, and initiation and 
elongation factors.95 By only including the translation factors that are essential to translation, and omitting 
all other competing components, including aaRSs, RFs, and RRFs, all 64 sense codons can be reassigned 
to unnatural amino acids. This method afforded the first high-yielding mRNA directed synthesis of unnatural 
α-peptides possible. Figure 1.13 
 
Figure 1.13 Purified Translation System95 
Furthermore, the absence of competing factors allowed them to assay the ribosome’s compatibility with 
unnatural backbones. They found that N-alkyl amino acids, α,α-disubstituted amino acids, and α-hydroxy 
acids are incorporated with high efficiencies into tripeptides, but D- and β-amino acids are not detected. 
Figure 1.14  
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Figure 1.14 Backbone analogs incorporated with the purified translation system 
Perhaps the main drawback of this particular study is that amino acid incorporation was quantified 
using a radioactive third amino acid, instead of the initiator tRNA being radioactive. Therefore, it was not 
possible to ascertain whether D- or β-amino acids were good acceptors, but poor peptidyl donors due to 
their inability to translocate or assume the correct spatial arrangement in the PTC for peptide bond formation 
following translocation. This assay was also combined with mRNA display to build peptide libraries where 
multiple sense codons were reassigned to α-amino acids with unnatural side chains.96 Furthermore, it 
provides the perfect platform to study the mechanism of incorporation of UAAs. For example, the ribosome 
does polymerize linear and cyclic N-alkyl amino acids but efficiency depends on the N-substitution sterics 
and nucleophile basicity.97,98 However, successful implementation of this technology requires the 
purification of each translation component and chemical synthesis for misacylating tRNAs, which are both 
time-consuming, therefore making this assay difficult to use in the large scale synthesis of unnatural 
backbone oligomers. 
 
Coupling ribozyme catalyzed tRNA aminoacylation with reconstituted cell-free translation systems 
for the synthesis of backbone oligomers 
The chemical aminoacylation of UAA-tRNAs was essentially rendered obsolete once the flexizyme 
was developed. The flexizyme, engineered by the Suga group, is a ribozyme that catalyzes tRNA 
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aminoacylation of any amino acid on any tRNA. 99,100 The flexizyme aminoacylates tRNAs by recognizing 
an aromatic motif on an amino acid and the conserved 3’ CCA end of a tRNA.  
 
Figure 1.15 Charging tRNAs with the flexizyme99,100 
The key to the universal aminoacylation of tRNAs using the flexizyme is that its recognition motifs are 
independent of the amino acid, as long as an aromatic motif is present in the amino acid side chain or on 
the acyl donor. Compared to the chemical aminoacylation method, charging a tRNA with the flexizyme is 
straightforward; there is no protein purification involved since the flexizyme is prepared using simple 
molecular biology techniques, such as PCR and in vitro run-off transcription. While the chemistry employed 
to prepare amino acid derivatives for tRNA charging involves multiple steps, they are straightforward and 
high-yielding, making this method much more accessible to scientists across many different fields. 
Combining this technology with a reconstituted cell-free translation system hastened the in vitro ribosomal 
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synthesis of peptides containing amino acids with unnatural side chains and backbones, including α-
hydroxy acids, N-methyl amino acids, D-amino acids and β-amino acids (see below for further discussion). 
Furthermore, this technology is amenable to the rapid and facile engineering of monomer sequences to 
facilitate the post-translational cyclization of unnatural oligomers. Below, I will discuss the different amino 
acid backbone analogs that have been incorporated using the flexizyme aminoacylation approach. 
 
1.1.1 α-hydroxy acids 
α-hydroxy acids have been shown to be suitable substrates for the ribosome, but their incorporation 
had not been confirmed directly. By using chemically aminoacylating tRNAs with lactic acid and phenyl 
lactic acid, the TM was deemed compatible with the purified translation system.101 The TM mediated 
synthesis of polyesters was achieved by using the flexizyme technology to aminoacylate tRNAs. Using this 
method, arbitrary codons were assigned to α-hydroxy aminoacyl-tRNAs and polyesters tagged with a C-
terminal flag were synthesized.102  This method was also used to achieve the mRNA-directed polyester 
synthesis with specific sequences.103 In both cases, the resulting polyesters contained a C-terminal flag 
peptide, so when they were base treated, the resulting α-hydroxy-flag peptides were analyzed using MALDI-
TOF and gel electrophoresis. Based on the product’s molecular weight and migration by gel 
electrophoresis, it was shown that the TM can synthesize up to 12-mer polyesters. However, in both cases, 
they were unable to incorporate more than 12 α-hydroxy acids, probably due to the slow ribosomal 
formation of polyesters and the low affinity of α-hydroxy acids for EF-Tu,102 thus limiting the number of α-
hydroxy aminoacyl-tRNAs that can be incorporated in vitro.  
 
1.1.2 N-alkyl amino acids 
N-alkyl amino acids have been one of the more amenable backbone analogs to be incorporated by 
the ribosome in cell-free translation systems, and similar results were obtained in the purified translation 
systems. Sense codon suppression has shed light on the single site and multiple site incorporation of N-
alkyl amino acids into linear as well as cyclic N-alkyl peptides.104,105 For example, N-alkyl amino acids are 
incorporated into peptides as long as the N-substitutions are non-bulky, aliphatic or aromatic; bulky and 
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charged N-substituted amino acids are not incorporated. As long as these requirements are followed, 
ribosomes can synthesize oligomers containing up to four consecutive N-alkyl amino acids.  
 
1.1.3 D-amino acids 
 D-aminoacyl tRNAs were shown to be successful initiator tRNAs.106  Furthermore, the incorporation 
of D-amino acids with yields ranging from 10%-65% was achieved by optimizing the EF-Tu and aa-tRNAs 
concentrations to facilitate D-aa-tRNA incorporation.107 Combining the flexizyme technology with the 
purified, reconstituted translation system allowed for the first mechanistic study of D-aa incorporation to 
investigate why the efficiency of D-amino acid incorporation has been reported as low. 108 D-aa-tRNAs were 
incorporated into di- and tripeptides to test their donor and acceptor abilities. They showed that D-amino 
acids are efficiently delivered to the ribosomal A site, they are efficient peptide chain acceptors, and the 
resulting peptidyl-tRNA containing the D-aa is translocated efficiently. However, the D-amino acid 
containing peptidyl-tRNA are poor peptide chain donors. The inability of D-amino acid containing peptidyl-
tRNA to act as efficient peptide chain donors leads to a large population of ribosomes that are arrested, 
and a small population that continues to translate efficiently. The translational arrest of the ribosomes was 
attributed to the D-amino acid rendering the PTC inactive. 
 
1.1.4 β-Amino Acids 
In 2016, the Suga group published the first report of multiple β-amino acid incorporations by a 
purified translation system.109 Just like with D-amino acids, their approach consisted of optimizing their 
reconstituted translation system by adjusting the EF-Tu and β-aa-tRNA concentrations to facilitate ternary 
complex formation, β-aminoacyl-tRNA delivery to the ribosome, and β-aminoacyl-tRNA accommodation on 
the A site. Using an mRNA coding for five natural amino acids, followed by the β-amino acid and a FLAG 
peptide, they found they were able to incorporate 13 different β-amino acyl-tRNAs with 50% efficiency. 
They noted that as the size of the β-aminoacyl-tRNA side chain increased, the lower the β-amino acid 
incorporation yield obtained. When they tried to translate two consecutive β-aa-tRNAs, they did not obtain 
the expected peptide. However, when they added a natural amino acid spacer between two β-amino acids, 
the yields were recovered. They attributed this result to the conformational flexibility two β-aminoacyl-tRNAs 
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in the PTC might prevent these aa-tRNAs to adopt the proper conformation for peptide bond formation. 
This result led them to incorporate three β-aminoacyl-tRNAs with a natural amino acid spacer that varied 
between one, two and, three amino acids. They credited the success of this result to the fact that multiple 
β-aa-tRNA incorporations might require an amino acid linker between each β-amino acid.  
 
Evolving the TM to incorporate D- and β-amino acids 
One way to circumvent the intractability of D- and β-amino acids with the TM is to mutate the PTC 
bases that are implicated in peptide bond formation. This approach was first tested with D-amino acids. 
The PTC was mutated using directed evolution to yield mutant ribosomes that accommodate the D-amino 
acid stereochemistry, and as a result, incorporate D-amino acids.110,111 These results motivated the Hecht 
group to mutate the PTC to yield mutant ribosomes that incorporate β-amino acids.112–114 Based on the 
observation that β-puromycin inhibit translation even though they have low affinity for eukaryotic 
ribosomes,115 the Hecht group screened a library of ribosome with PTC mutations. The PTC mutations 
used in this report were adapted from a previous report where mutant ribosomes that are not as sensitive 
to D-amino acids were discovered.110 To select ribosomes with the desired mutations, they used a double 
selection with β-puromycin and erythromycin, an antibiotic that inhibits PTC activity. β-puromycin allowed 
them to select for ribosomes that could tolerate the β-aminoacyl moiety, while erythromycin allowed them 
to select against wild-type ribosomes in vivo. Based on their double selection, the Hecht group obtained S-
30 extracts with mutant ribosomes that not only incorporate natural amino acids but also β-alanyl-tRNACUA 
in response to the UAG stop codon in DHFR, P. pyralis firefly luciferase, and O. madagascariensis scorpion 
IsCT peptide.113 These mutant ribosomes were later tested for their ability to incorporate β-Phe β,β-
dimethyl-β-alanine, β-(p-bromophenyl)alanine, and α-methyl-β-alanine in response to the UAG stop codon 
embedded in the middle of the DHFR sequence using S-30 extracts.112 In order to incorporate different 
stereo- and regioisomers of β-amino acids, the Hecht group subjected the library of ribosome mutants to 
two other rounds of directed evolution using two additional β-puromycin analogs, where the R group is 
attached to the C2 (β2-puromycin) and C3 (β3-puromycin).114 Their search resulted in mutant ribosomes 
that could incorporate β2-alanine and β3-alanine with R and S configurations at the C2 and C3 carbon 
respectively into full-length DHFR. Figure# While these mutant ribosomes provide an alternative for the 
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incorporation of β-amino acids into full proteins, and they have been used to incorporate β3-Phe-tRNAPhe 
analogs in vivo,116 both methods has several limitations. The in vitro translations are carried out in the 
presence of RFs that compete with stop codon suppression. The in vivo incorporations are limited by the 
number of sense codons can be replaced, which would limit the synthesis of diverse β-peptide libraries.  
 
Summary and Thesis Overview 
The TM is an important biosynthetic tool for building large libraries of synthetic peptides. However, 
the TM machinery is limited by the types of monomers it accepts, which limits the diversity of peptide-
mimetic libraries. While TM structural and mechanistic studies has expedited the development of 
technologies to synthesize peptides with unnatural backbones, such as α-hydroxy acids and N-alkyl amino 
acids, D- and β-amino acids continue to be difficult substrates for the natural TM. Because modifying the 
TM is labor-intensive, identifying alternate ways of incorporating these intractable monomers remains an 
important goal.  
In this thesis, I use β-amino acid backbone to yield α-hydroxy-β-amino acids. The α-hydroxy moiety 
provides an alternate pathway for the incorporation of β-amino acids using the natural TM. In Chapter 2, I 
describe the proof-of-concept experiments that show that α-hydroxy-β-aminoacyl-tRNAs are suitable A-site 
and P-site substrates. I show that these monomers are incorporated through the formation of an ester bond 
that undergoes a rapid rearrangement to yield an amide bond. In Chapter 3, I expand on the single 
incorporation of α-hydroxy-β-amino acids results to show that the ribosome incorporates multiple α-
hydroxy-β-amino acids and discuss the limitations of this technology. Finally, I list the materials and 
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2 Chapter 2 The ribosomal incorporation of single α-hydroxy-β-amino acids 
Introduction 
β-amino acids are important building blocks for the synthesis of biologically relevant 
peptidomimetics because they provide enhanced proteolytic stability in vivo and in vitro.1  However, the full 
therapeutic potential of β-amino acid-based peptidomimetics has not been realized due to their limited 
production by time-consuming synthetic methods, such as solid phase peptide synthesis (SPPS). While 
SPPS approaches are applicable to any building block, a small peptide on the order of 41 amino acids can 
take up to 82 hours to synthesize, which is not practical for the large-scale production of peptidomimics.2  
In addition, SPPS becomes increasingly inefficient as the size of the peptide grows, due to incomplete 
deprotection and coupling steps.3,4  
Thus, researchers have turned to other methods to ease the production of β-amino acid containing 
proteins and peptides. One alternative approach involves the expressed protein ligation method, which 
involves attaching a synthetic peptide to a recombinant protein.5  Although this method can successfully 
produce proteins containing unnatural amino acids, the modified protein requires several steps to assemble, 
including the overexpression and purification of the recombinant protein, the synthesis of the unnatural 
peptide, and the actual ligation step. Another approach uses the translation machinery to incorporate β-
amino acids. Initially, β-amino acids were considered intractable ribosomal substrates, however, the Suga 
group was able to synthesize β-amino acid-based peptides in vitro by adjusting the EF-Tu and aa-tRNA 
concentrations.6  Although Suga and coworkers were able to successfully adapt the translation machinery 
to produce β-amino acid peptides, they reported only 50% sense suppression relative to the control peptide.  
Here, we propose a method that improves the adaptation of the translation machinery (TM) for the 
production of β-amino acid peptides by modifying the β-amino acid carbon backbone to increase its 
incorporation in vitro. Because the ribosome can polymerize α-hydroxy acids,7–13 and acyl shifts are well 
documented in the literature,14–16 we hypothesized that the presence of the α-hydroxy moiety would 
encourage the ribosome to incorporate α-hydroxy-β-amino acids via the formation of an ester bond that 
would rapidly rearrange to form the amide bond (Scheme 2.1).  
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Scheme 2.1 Proposed mechanism for the ribosomal incorporation of α-hydroxy-β-amino acids 
 
In this work, I test the α-hydroxy-β-amino acid rearrangement hypothesis by measuring the 
conversion of 35S-fMet-tRNAfMet to di- and tripeptides using a reconstituted in vitro translation system with 
three α-hydroxy-β-aminoacyl-tRNAs. I successfully demonstrate that the ribosome incorporates α-hydroxy-
β-aminoacyl-tRNAs through the formation of an ester bond that is uniquely positioned to undergo an O, N 
acyl shift to yield a native peptide bond. Moreover, α-hydroxy-β-aminoacyl-tRNAs are incorporated with 
efficiencies comparable those observed with natural substrates. This approach represents the first time the 
functionalization of an unnatural amino acid backbone results in the successful ribosomal incorporation of 
a previously intractable substrate.  
 
Results 
2.1.1 Selection and Synthesis of α -hydroxy-β-aminoacyl-tRNAs 
 To probe the ribosomal compatibility of α-hydroxy-β-amino acids, we selected isoserine (Iso, B), 
(2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acids (β-Phe, C), and (2S,3S)-3-amino-2-hydroxy-5-
methylhexanoic acid (β-Leu, D), which both vary in size, hydrophobicity, and electrostatics. The α-hydroxy-
β-amino acids were charged onto tRNAPhe to ensure that peptide bond formation was not inhibited by high 
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tRNA body binding affinity to the ternary complex.17  Using the flexizyme technology, the tRNAPhe was 
misacylated according to the procedure outlined by Suga et.al.18  
 
2.1.2 Framework for evaluating the ribosomal compatibility of α -hydroxy-β-aminoacyl-tRNAs 
The reconstituted translation system was as previously described.19 Based on this system, two 
assays were designed to study the incorporation of the different α-hydroxy-β-aminoacyl-tRNAs - a dipeptide 
assay and a tripeptide assay. The dipeptide assay evaluates the compatibility of α-hydroxy-β-aminoacyl-
tRNAs with the translation machinery and its acceptor activity. The tripeptide assay evaluates α-hydroxy-
β-aminoacyl-tRNAs peptide bond donor activity. Because translations are initiated [35S]-fMet-tRNAfMet, 
peptide products were quantified by electrophoretic thin layer chromatography (eTLC). Since eTLC 
resolves peptides based on their charge, Lys-tRNALys or Arg-tRNALys were selected as the third amino acid. 
To confirm the identity and yields of the peptides, I mixed and co-injected the radioactive translation product 
with the chemically synthesized authentic peptide marker, and analyzed them on an HPLC with a β-RAM 
and a UV detector. The β-RAM detector corroborated radioactive peptide yields obtained by eTLC, while 
co-migration of the β-RAM signal and UV signal validated the peptide identity. The expected peptide 
products are shown in Scheme 2.2.  
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Scheme 2.2 Expected translation products with α-hydroxy-β-amino acids 
2.1.3 Ribosomal synthesis of dipeptides containing a single α -hydroxy-β-amino acid  
Using α-hydroxy-β-aminoacyl tRNAPhe with our purified in vitro translation system, and analyzing 
the peptide products by eTLC and HPLC β-RAM, I demonstrate that the ribosome synthesizes dipeptides 
containing α-hydroxy-β-amino acids (Figure 2.1). I observed ≥70% radioactive fMet converted to both 
natural and unnatural dipeptide, suggesting that the yields obtained with α-hydroxy-β-aminoacyl-tRNAPhes 
are comparable to what was obtained with the control Phe-tRNAPhe. Finally, my dipeptide results indicate 
that α-hydroxy-β-aminoacyl tRNAPhe are efficient peptide donors.  
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Figure 2.1 Ribosomal incorporation of α-hydroxy-β-amino acids into dipeptides 
2.1.4 Ribosomal synthesis of tripeptides containing a single α-hydroxy-β-amino acid  
To determine the ribosome’s ability to act as peptide acceptors, and therefore their potential for any 
future application involving the ribosomal polymerization of α-hydroxy-β-amino acid, I translated the 
tripeptide B1. Even though the yields for the tripeptide were somewhat lower than for the dipeptides (50-
60% fMet conversion to tripeptide), we were able to show by eTLC that α-hydroxy-β-aminoacyl-tRNAPhe is 
also an efficient peptide acceptor during translation. Curiously, when we attempted to confirm these results 
using HPLC-β-RAM co-injection with the synthetic authentic markers, the authentic marker trace and 
translation trace peak did not co-migrate. These results suggested that while Lys was incorporated, the 
identity of the final peptide did not match the authentic peptides. Based on these results, I hypothesized 
that the lysine side chain was interfering with the expected O, N acyl shift. To address this problem and 
minimize the number of changes to the system, I charged Arg onto tRNALys using the flexizyme technology 
discussed in Chapter 1, and translated peptide B2. When Lys was replaced with Arg, the translation yields 
were not only higher by eTLC (≥70%), the authentic markers matched the authentic tripeptide peak and the 
yields observed by eTLC (Figure 2.2).  
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Figure 2.2 Ribosomal incorporation of α-hydroxy-β-amino acids into tripeptide 
2.1.5 Control Experiments 
 Next, we tested our hypothesis for the ribosomal incorporation of α-hydroxy-β-aminoacyl-tRNAPhe 
detailed in Scheme 1. Based on the ribosome’s ability to incorporate esters, we postulated a two-step 
mechanism for the incorporation of α-hydroxy-β-amino acids. First, α-hydroxy-β-aminoacyl tRNAPhe would 
form an intermediate ester bond. Because the amine is unique positioned to attack the ester’s carbonyl 
carbon, the peptide would undergo a spontaneous O, N acyl shift to yield a base-stable amide bond. The 
feasibility of this premise was tested by replacing isoserine-tRNAPhe with two control aa-tRNAs, Lac-tRNAPhe 
and β-alanine-tRNAPhe. These two control aa-tRNAs were chosen as they are Iso analogs. Lac-tRNAPhe 
has the α-hydroxy moiety but lacks the α-amine, while β-alanine-tRNAPhe contains the α-amine but lacks 
the α-hydroxy moiety. The experimental conditions and expected results are detailed in Scheme 2.3 
Cartoon representation of control reactions.  
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Scheme 2.3 Cartoon representation of control reactions 
To determine whether the α-hydroxy-β-amino acids are incorporated via an ester bond that 
rearranges to form an amide bond, I quenched the four tripeptides, 2, 3, 4, and 5 with the three conditions 
detailed in Scheme 3 and compared the resulting eTLC patterns. First, I incubated the translation reactions 
with puromycin (pmn) (Scheme 2.3) because it releases the peptide chain from the peptidyl tRNA without 
interfering the ester backbones. Then, I treated the puromycin-terminated peptides with base (Scheme 3B). 
As a result, any peptides with an ester bond would be cleaved and result in an increase of fMet observed 
by eTLC. Finally, treating the peptides only with base would cleave all the ester bonds in the reaction 
(Scheme 2.3). Most importantly, if the amino acid is not being incorporated into the peptide chain, we would 
observe fMet-pmn with the first two conditions and fMet with the third condition.   
The results of the control experiments are shown in Figure 2.3 Control reactions. The control 
peptide 2 contains an amide bond, and therefore the patterns observed by eTLC are representative of 
peptides with base-stable amide backbones. The patterns observed with the control peptide 4 correspond 
to the presence of an ester bond in the peptide backbone. When peptides with ester backbones are 
released with puromycin (Figure 2.3, lane 4a), we observe the formation of a tripeptide. However, when 
peptide 4 is released with puromycin and then base treated (Figure 2.3, lane 4b) or just base treated, 
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(Figure 2.3, lane 4c), only fMet is observed. Control peptide 5 contains a classic, unaltered β-amino acid 
that is not compatible with the TM.12  The patterns observed with peptide 5 illustrate is consistent with the 
unsuccessful incorporation of β-aminoacyl-tRNAs by the TM. When I evaluate the patterns observed with 
peptide 3 with the three conditions outlined above, it is clear that the resulting peptide contains an amide 
bond, and not a base-labile ester bond (Figure 2.3, Lanes 3a, 3b, 3c). This result validates my conclusion 
that the ribosome incorporates α-hydroxy-β-aa-tRNAs through the formation of an ester bond that rapidly 
rearranges through an O, N acyl shift to yield the native peptide bond.  
 
Figure 2.3 Control reactions 
Note: Lane 1 is the control lane to visualize where fMet and fMet-pmn migrates by eTLC. Lane 3c 
indicates the peptide 3 and fMet-pmn co-migrate by eTLC 
2.1.6 Discussion 
Peptidomimetics have many potential therapeutic applications, as they assume secondary 
structures akin to the secondary structures observed in natural proteins, and therefore act as efficient 
modulators of protein activities.20  However, their synthesis, which mostly relies on SPPS, limits the length 
of the peptides and restricts the size and diversity peptidomimetic libraries. Therefore, using the TM would 
provide an alternative way to synthesize these important targets. Unfortunately, most reports suggest that 
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the natural TM discriminates against amino acids with unnatural backbones, such as β-amino acids.10,12,21,22 
In this study, we proposed altering the β-amino acid backbone by functionalizing the α-carbon with a 
hydroxyl group, which would ideally to lead the ribosome into incorporating β-amino acids through the 
formation of an ester bond that rapidly rearranges to form an amide bond. 
My results indicate that the O, N acyl rearrangement is compatible with the TM and is independent 
of side chain structure. Furthermore, base quenching resulted in di- and tripeptides, and not fMet, 
confirming that the O, N acyl shift is complete after 1h. This conclusion is supported by our control 
experiments with Lactic acid and β-alanine, which confirm that α-hydroxy acids are compatible with the 
translation machinery, but β-amino acids are not. Therefore, if α-hydroxy-β-aminoacyl-tRNAPhes were being 
incorporated via the primary amine, I would most likely observe low peptide yields or no peptide formation. 
However, because I observe yields that are comparable to those obtained with the control peptide, the 
mechanism is validated.  
The eTLC patterns were identical when Lys (Scheme 2.2, B1) or Arg (Scheme 2.2, B2) were in the 
third position, but the B2 yields are about 20% higher than B1 yields. Furthermore, when B1 translations were 
co-injected with the synthetic authentic markers, the β-RAM traces did not align with the UV trace from the 
chemically synthesized authentic marker. However, when I co-injected the B2 translations with the 
corresponding authentic marker, I confirmed that B2 connectivity is consistent with the expected natural 
amino acid connectivity.  
My results indicate that Lys interferes with the formation of expected peptide, B1. By keeping the 
tRNALys body consistent and changing the identity of the charged amino acid from Lys to Arg, I was able to 
rule out any problem with the tRNA body. I concluded that the lysine side chain is interfering with the 




2.1.7 A proposed mechanistic model for the formation of B3 
I envision three distinct scenarios where the Nε could be interfering with the O,N acyl shift by 
reacting with one of the two electrophilic carbons, labeled C2 and C4 in Scheme 5A.1 These four scenarios 
are outlined in Scheme 2.4.  
 
Scheme 2.4 Possible rearrangement mechanisms for the formation of isopeptide 
Scenario 1: Nβ attacks C2, a 5-membered ring intermediate forms during O,N acyl shift, yielding a 
translation product, whose β-RAM trace aligns with the UV authentic marker trace.  
Scenario 2: Nβ attacks C4, forming a 7-membered ring intermediate before the O,N acyl occurs. 
Upon quenching with base, the ester bond that links the 7-membered ring to fMet is cleaved and 
only fMet would be visible by eTLC. 
Scenario 3: Nε attacks C4 to form a 7-membered ring lactam that is bonded to fMet by an ester 
bond. When the lactam is treated with base, fMet would be the only visible product.  
Scenario 4: If Nβ attacked C4, then an 11-membered ring intermediate would form during the O,N 
acyl shift. This leads to the formation of a base-stable isopeptide, B3.  
                                                       
1 This mechanism does not include the amides, which could also act as nucleophiles in the presence of 
water when subjected to extreme heat.30 
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My results seem to be consistent with Scenario 4. In view of the fact that the ribosome’s catalytic 
activity is entropy driven,23 I can infer that the lysine side chain is uniquely positioned to react with the ester 
intermediate before the expected O, N acyl shift occurs. This stabilization would yield isopeptide, B3. Since 
eTLC detects the charge of the peptides and not their connectivities, B3 is resolvable by eTLC but its altered 
connectivity affects HPLC retention times. Therefore, the β-RAM traces do not match the authentic marker 
traces. While the ribosomal synthesis of B3 would rely on the 11-membered ring formation, which is rarely 
observed probably due to unfavorable steric interactions of 11-membered rings, there is a recent report that 
suggests 11-membered ring intermediates are possible with S, N acyl shifts.24 Furthermore, because the 
pre- and post-catalysis X-ray structures published by the Ramakrishnan laboratory that suggest that the 
peptidyl transferase center (PTC) is dynamic, we could suggest that the PTC might accommodate and 
stabilize the 11-membered ring transition state.25  
 
Conclusion and Future Directions 
 The single site incorporation of α-hydroxy-β-amino acids using our reconstituted in vitro translation 
system provides a robust approach for synthesizing peptides and proteins containing β-amino acids 
monomers. Intramolecular and intermolecular acyl shifts have been used in native chemical ligation to 
create longer proteins,26,27 synthesize small molecule drugs,28 and observed in autoproteolysis.29 However, 
to our knowledge, this is the first time that an intramolecular O,N acyl shift has been applied in the ribosomal 
synthesis of peptides containing unnatural backbones. Even more striking, this provides a novel approach 
for the synthesis of isopeptides by the ribosome. While the identity of the isopeptide is yet to be directly 
confirmed by co-migration with the authentic isopeptide marker, both of these approaches are widely useful 
for the synthesis of backbone analogs of natural peptides. For example, if we replace the α-hydroxy with 
an α-thiol, the peptide could be incorporated through the formation of a thioester that would undergo a 
spontaneous S,N acyl shift to yield peptides with the α-thiol-β-amino acid backbone. Subjecting these 
peptides to reducing conditions using Raney Nickel would yield a peptide with an unsubstituted β-backbone 
analog. Another interesting study would involve the polymerization of α-hydroxy-β-amino acids to yield 
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3 Chapter 3 The ribosomal incorporation of multiple α-hydroxy-β-amino acids 
Introduction 
β-peptides foldamers are peptidomimetics that mimic native protein folding patterns under 
physiological conditions.1  Unlike their α-peptide analogs, β-peptides, and specifically α-hydroxy-β-amino 
acids, are inherently stable to protease degradation.2,3  Notably, β-peptides foldamers have been 
engineered to target several aberrant protein protein interactions (PPIs) such as the p53•hDM2 interaction, 
which has been implicated in tumor growth, and gp41, which is required for HIV host cell infection.4–6 
Despite their promise, the main strategy used to synthesize β-peptides foldamers has relied on solid phase 
peptide synthesis (SPPS), which is not optimal for the synthesis of diverse peptide libraries.7  Therefore, 
developing new techniques to quickly and efficiently synthesize β-peptides foldamers and to generate 
structurally diverse libraries for high-throughput screening will facilitate the discovery of new drugs to treat 
diseases associated with aberrant PPIs.  
The reconstituted in vitro translation system has been manipulated to synthesize peptides with a 
variety of unnatural amino acids (UAAs). In this system, UAAs are incorporated into a growing peptide chain 
by reassigning sense codons in the messenger RNA (mRNA) to specific UAAs by removing any competing 
factors, such as RF and aaRS.8  Most importantly, reconstituted translation systems can be combined with 
in vitro selection technologies, such as mRNA display, to identify unnatural peptides that bind to specific 
protein targets.9  However, using display technologies to synthesize β-peptides foldamers requires that β-
aminoacyl-tRNAs are compatible with the translation machinery (TM). Unfortunately, several reports 
suggest that β-aminoacyl-tRNAs are incompatible with the natural TM.8,10,11  
In Chapter 2, I showed that α-hydroxy-β-amino acids are efficiently incorporated by the TM. 
Analysis of di- and tripeptide translations by electrophoretic thin layer chromatography (eTLC) and HPLC 
β-RAM revealed that α-hydroxy-β-amino acids function as peptide chain acceptors and peptide chain 
donors. In addition, I showed that these new substrates are incorporated as esters that undergo a rapid O, 
N acyl shift to yield a native peptide bond. Given these initial successes, I next set out to test the ability of 
the ribosome to incorporate α-hydroxy-β-amino acids at multiple sites within the same peptide. I 
hypothesized that multiple α-hydroxy-β-amino acids can be incorporated through the formation of a 
polyester, that would subsequently undergo consecutive O, N acyl shifts to yield a polyamine. Since the 
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ribosome-catalyzed polyester synthesis has been validated on three different occasions,13–15 I hypothesized 
that we could use the reconstituted in vitro translation system to synthesize peptides with multiple 
consecutive α-hydroxy-β-amino acids as well as peptides with alternating α-amino acids (Scheme 3.1).  
 
Scheme 3.1 Multiple site incorporation of α-hydroxy-β-amino acids 
If successful, this would provide a new avenue for synthesizing libraries of structurally diverse peptides 




3.1.1 Developing a framework to evaluate the ribosomal incorporation of multiple α-hydroxy-β-amino 
acids 
To investigate the effect of side chain size, hydrophobicity, and electrostatics on the ribosomal 
incorporation of multiple α-hydroxy-β-amino acids, tRNAPhe was charged with its cognate amino acid, 
phenylalanine (Phe; a), and with three distinct α-hydroxy-β-amino acids: Isoserine (Iso, b), (2S, 3S)-3-
amino-2-hydroxy-4-phenylbutyric acid (β-Phe, c), and (2S,3S)-3-amino-2-hydroxy-5-methylhexanoic acid 
(β-Leu, d).  
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Four different mRNAs encoding the peptides indicated in Scheme 3.2 were used in translation 
experiments. These include mRNAs encoding two consecutive α-hydroxy-β-amino acids (Scheme 3.2; 
mRNA A; target peptides A1b-d and A2b-d), three consecutive α-hydroxy-β-amino acids (Scheme 3.2;mRNA 
B; target peptides B1b-d and B2b-d), two α-hydroxy-β-amino acids separated by a single α-amino acid spacer 
(Scheme 3.2; mRNA C; target peptides C1b-d and C2b-d), and two α-hydroxy-β-amino acids separated by a 
three α-amino acid spacer (Scheme 3.2; mRNA D; target peptides D1b-d and D2b-d). Note that because eTLC 
resolves peptides based on their charge, I chose Lys (A1, B1, C1 and D1) or Arg (A2, B2, C2, and D2) as 
the final amino acid to facilitate separation and quantification by eTLC.  
 
Scheme 3.2 Experimental setup for the ribosomal incorporation multiple of α-hydroxy-β-amino acids 
3.1.2 The ribosome can incorporate two consecutive α-hydroxy-β-amino acids - Target Peptides A1 and 
A2 
To investigate the efficiency with which the ribosome can incorporate two consecutive α-hydroxy-
β-amino acids, I began by translating the mRNAs encoding tetrapeptide A1a-d and A2a-d . The tetrapeptide 
yields for A1a and A2a, the positive controls containing two consecutive Phe residues, were in both cases 
~80% (Figure 3.1). Relative to this control reaction, the yields for the tetrapeptides containing two 
consecutive α-hydroxy-β-amino acids were ~3 to 4-fold lower (20-25%) when the peptides ended with Lys, 
but only ~1.5 to 2-fold lower (40-55%) when the same peptides ended in Arg. These results are consistent 
with the results described in Chapter 2 where I showed that tripeptide yields for a single β-amino acid 
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incorporation event were greater when the peptide ended with Arg. Taken together, these results suggest 
that the ability of β-amino acids to function as peptide-chain donors is controlled at least in part by the 
nature of the peptide-chain acceptor in the A site. 
 
Figure 3.1 The ribosomal incorporation of two, consecutive α-hydroxy-β-amino acids 
Note: The eTLC to the left represents the translations A2a-d 
 
3.1.3 The incorporation of three consecutive α-hydroxy-β-amino acids arrests translation - Target 
Peptides B1 and B2 
Next, I investigated whether the ribosome could incorporate three consecutive α-hydroxy-β-amino acids 
by translating the mRNAs encoding pentapeptides B1a-d and B2a-d (Figure 3.2). With the exception of peptide 
B2b, the pentapeptide yields for all of the mRNAs encoding three consecutive α-hydroxy-β-amino acids were 
~10% or lower, compared to ~90% for the control pentapeptide containing three consecutive Phe residues. 
Instead, the results reveal the accumulation of either di-, tri- or tetrapeptide. In contrast, the mRNA encoding 
peptide B2b resulted in pentapeptide yields of ~40%. 
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Figure 3.2 The ribosomal incorporation of three, consecutive α-hydroxy-β-amino acids 
Note: The eTLC to the left represents the translations B2a-d 
 
3.1.4 Placing α-amino acid spacers between the α-hydroxy-β-amino acids increases β-peptide yields - 
Target peptides C1 and C2 vs Target peptides D1 and D2 
I next sought to determine whether the addition of α-amino acid spacers between the α-hydroxy-β-amino 
acids would improve their incorporation efficiency. The ribosomal incorporation of two α-hydroxy-β-amino 
acids separated by a single α-amino acid spacer is shown in Figure 3.3. The results show that for most of 
the pentapeptides containing a single α-amino acid spacer (C1b, C1c and C1d, and C2c and C2d) there was a 
significant reduction in full-length peptide yields (compare tetrapeptide yields in Figure 3.1 with 
pentapeptide yields in Figure 3.3). Interestingly, the results reveal the accumulation of a major radioactive 
species that appears to correspond to the formation of a tetrapeptide intermediate. This suggests that both 
of the α-hydroxy-β-amino acids were incorporated, but failed to function as peptide chain-donors. To ensure 
that the accumulated product corresponding to tetrapeptide, control translation reactions were performed 
with Phe-tRNAPhe, which yielded tri-, tetra-, and penta-peptide (Figure 3.).  
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Figure 3.3 The ribosomal incorporation of two α-hydroxy-β-amino acids separated by a single α-amino acid 
spacer 
Note: The eTLC to the left represents the translations C2a-d 
 
 
The final yield for pentapeptide C2b  (50%) was essentially the same as the tetrapeptide yield observed in 




Figure 3.4 Translation of control peptides, fMFK, fMFKF, and fMFKFK 
 
 
Unlike the results obtained with a single α-amino acid spacer, the addition of a three α-amino acid 
spacer between two α-hydroxy-β-amino acids resulted in a significant increase in the ribosomal 
incorporation of two α-hydroxy-β-amino acids (Figure 3.4). Relative to the yields obtained with a single α-
amino acid spacer, the addition of a three α-amino acid spacer resulted in a ~10-fold increase in the full-
length peptide yields for peptides D1b-d. The full-length peptide yields for peptides D2b-d were ~1.5-fold higher 
than those observed for the D1 peptides. Notably, the results were not side chain dependent.  
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Figure 3.4 The ribosomal incorporation of two α-hydroxy-β-amino acids separated by a three α-amino 
acid spacer 
Note: The eTLC to the left represents the translations D2a-d 
Discussion 
Despite the interest in β-peptides foldamers for their proteolytic stability and ability to self-assemble into 
secondary structures that mimic protein surfaces, their synthesis relies in SPPS, which is not practical for 
building diverse libraries of these peptidomimetics. We hypothesized that we could circumvent this problem 
by using the TM to synthesize peptides with α-hydroxy-β-amino acids. In Chapter 2, I confirmed that the 
TM incorporates these monomers into dipeptides and tripeptides using eTLC and HPLC β-RAM to calculate 
peptide yields and confirm peptide identities. In this chapter, I expanded upon the results obtained in 
Chapter 2 by testing the ability of the TM to incorporate multiple α-hydroxy-β-amino acids within the same 
peptide. By varying the identity of the charged amino acid, translating four different mRNAs and quantifying 
the results via phosphorimager analysis, I demonstrate that the TM can successfully synthesize peptides 
with two α-hydroxy-β-amino acids.  
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3.1.5 The ribosomal incorporation of multiple α-hydroxy-β-aminoacyl-tRNAs exhibits a side chain 
dependence 
The most exciting finding to emerge from this study is the successful ribosomal incorporation of multiple 
α-hydroxy-β-amino acids within one peptide. However, it is worth noting that tetrapeptide and pentapeptide 
translations with Arg-tRNALys seem to be side-chain dependent. For example, translations with mRNAs A, 
B, and C show that Iso, which lacks a side chain, exhibits a higher final incorporation yield than β-Phe or 
β-Leu. This side-chain dependent incorporation indicates that sterics influence the ribosome’s catalytic 
activity. This concept is not new as several studies have shown that D-amino acids and other UAAs with 
bulky side chains are poor ribosomal substrates.18,19 Interestingly, this side chain dependence is not 
observed when I translate mRNA D. This result could indicate that any deleterious steric interactions within 
the PTC becomes less pronounced when a three α-amino acid spacer is included between the two α-
hydroxy-β-amino acids. 
 
3.1.6 Incorporating multiple adjacent α-hydroxy-β-amino acids triggers ribosome stalling 
The translation of mRNAs B and C results in a significant accumulation of intermediate product that 
is greater than the yields obtained for the desired full-length peptide. I interpret intermediate product 
accumulations as instances where the peptide structure induces ribosome stalling. While stalling was not 
observed in the single incorporation assays performed in Chapter 2, the multiple incorporation assay is a 
more stringent assay for TM activity.20  Furthermore, it is possible that the single incorporations of α-
hydroxy-β-amino acids may be affecting the PTC activity but the populations of ribosomes that are affected 
might be minor enough that they remain undetected. However, because the multiple incorporation assay is 
a more rigorous assay for the TM activity, a higher percentage of ribosomes become incompetent as a 
result of the multiple unnatural backbones in the PTC, making it possible to quantify peptide accumulations 
by eTLC. Meaning, when more than one α-hydroxy-β-amino acid is present in the PTC, any stalling events 
become cumulative and therefore, easier to detect. While it is difficult to characterize the nature of the 
stalling mechanism in this instance, we can attempt to explain the results based on previous 
characterizations of different stalling mechanisms, and therefore, propose experiments, to address the 
stalling and make this technology even more robust. Below, I will discuss the different in vitro stalling 
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mechanisms, how they relate to the multiple incorporation of α-hydroxy-β-amino acids, and propose 
experiments to rescue ribosome stalling, where appropriate.  
There are two known triggers of ribosome stalling – the nascent peptide interacting with the exit 
tunnel or the nascent peptide interacting with the PTC in an unproductive manner. The exit tunnel is located 
in the 50S subunit and is mostly composed of 23S rRNA, although ribosomal proteins L4 and L22 are also 
prominent structures found in the exit tunnel’s most constricted section. The tunnel is about 80-100 Å long, 
has a diameter that varies from 10 Å at the narrowest part and 20 Å at the widest part, and protects 30-40 
amino acids of an extended polypeptide chain.21,22 The growing polypeptide chain can adopt secondary 
structures similar to an α-helix as it transverses through the exit tunnel; in that case the exit tunnel can 
protect up to 60 amino acids.23 The exit tunnel is also sensitive to the sequences that are translated. For 
instance, short peptides containing prolines provoke ribosome stalling by interacting with the exit tunnel’s 
23S rRNA, inducing a conformational change in the 23S rRNA backbone that restricts PTC activity.24 
Ribosome stalling is also observed in the elongation of certain peptide sequences, such as proline and 
glycine polypeptides, where either the A-site tRNA accommodation, peptidyl transfer, or translocation steps 
are affected.25–27  Peptide chains do not reach the exit tunnel until they have reached about seven or eight 
amino acids in length (24.5-28Å).28 As a result, the stalling observed with the di-, tri-, and tetrapeptides is 
unlikely to occur as a consequence of unfavorable interactions with the exit tunnel.  
Ribosome stalling can also be triggered by premature peptidyl-tRNA drop-off which competes with 
translation elongation.29 Peptidyl-tRNA drop-off events occur when the concentration of a particular aa-
tRNA is low or completely absent. When aa-tRNA concentrations are low, they create ‘starved codons’ 
because ternary complex formation, its delivery to the ribosome and A-site decoding happen at a slower 
rate. In the case of UAA-tRNAs, the amino acid identity might affect the binding affinity for EF-Tu, which 
slows the rate at which they are delivered to the ribosome and thus lowers their incorporation efficiency.30–
32  Since the experiments described in this chapter are conducted with EF-Tu in 30-fold excess over the α-
hydroxy-β-aminoacyl-tRNAs, stalling is unlikely to originate from slow ternary complex formation, or α-
hydroxy-β-aminoacyl-tRNAPhe delivery to the A-site. However, it is possible that α-hydroxy-β-aminoacyl-
tRNAs bind EF-Tu in an inefficient manner, which increases the α-hydroxy-β-aminoacyl-tRNAPhe A-site 
sampling time. Measuring the binding affinity of α-hydroxy-β-aminoacyl-tRNAs to the ribosome using filter 
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binding assays would provide further insights into this step.33,34  It is also possible that the ribosomal A site 
discriminates against α-hydroxy-β-amino acids. Chemical probing experiments where the 23S rRNA 
protection patterns obtained with natural aminoacyl-tRNAs and α-hydroxy-β-aminoacyl-tRNA interactions 
would shed light on role of the amino acid in A-site accommodation. Furthermore, because the α-hydroxy-
β-amino acid backbone is more flexible than natural amino acid backbones due to the additional carbon,1 
the conformational flexibility of α-hydroxy-β-amino acids may keep the P- and A-site substrates from 
adopting the correct conformation in a timely fashion. This could also manifest as the accumulation of 
intermediate peptide products observed by eTLC. This explanation is particularly appealing since the 
ribosome’s main mechanism of action is lowering the activation energy of peptide bond formation by 
stabilizing the P- and A-site substrates in the correct conformation.35 If P- and A-site substrate stabilization 
becomes difficult with the multiple incorporation of α-hydroxy-β-aminoacyl-tRNAPhes, peptidyl drop-off may 
compete with the elongation step.  
Peptidyl drop-off can also be catalyzed by IF1/IF2 in systems where RFs are missing and there are 
‘starved’ codons, such as this one.36  IF1/IF2 catalyzed peptidyl drop-off is most effective when the ribosome 
is translating short messages that code for 5 amino acids or less,37  this biochemical observation could 
provide an alternate avenue for explaining intermediate product accumulation. If the A-site and P-site tRNAs 
are unable to adopt the proper conformation for peptide bond formation to occur, then IF1/IF2 could catalyze 
peptidyl drop-off. We can test this hypothesis using nitrocellulose binding assays to determine the 
percentage of peptidyl-tRNAs bound to the ribosome at different stages of elongation.  
Another possibility is that the O, N acyl shifts required for native peptide bond formation occur 
concurrently and co-translationally. If simultaneous rearrangements are incompatible with the large 
subunit’s 23S rRNA backbone, it could lead to conformational rearrangements within the 23S rRNA 
backbone that render the PTC inactive, regardless of the nature of the aa-tRNA being incorporated. Thus, 
the multiple O, N acyl shifts could trigger ribosome stalling. A direct way to test this hypothesis would be to 
block the O, N acyl shift from occurring by converting the amine to an azide (α-hydroxy-β-azide) and 
charging it onto tRNAPhe so that the only component that is different in the reactions is the aminoacyl moiety. 
Translating α-hydroxy-β-azide tRNAPhe and releasing the peptide with puromycin (pmn), would yield an 
ester with azides that can be reduced with tris(2-carboxyethyl)phosphine (TCEP). The TCEP reduction 
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would trigger the O, N acyl shifts that result in native amide bonds only after all the relevant aa-tRNAs have 
been incorporated. 
Translation stalling is mostly alleviated when mRNA D is translated. A potential explanation is that 
the heptapeptides containing the two α-hydroxy-β-amino acids are long enough to reach the exit tunnel (25 
Å and 26.56 Å for the natural and unnatural peptides, respectively). This could result in favorable 
interactions with 23S rRNA that reduces any problems within the PTC. Finally, because the identity of the 
A-site tRNA has been implicated in ribosome stalling, it might be interesting to change the identity of the 
charged aa-tRNAs to another amino acid, such as alanine or glutamine, to probe the effects of the incoming 
aa-tRNA on α-hydroxy-β-aminoacyl-tRNA elongation.38 This approach would be especially attractive as the 
identity of the A-site aa-tRNA has been implicated ribosome stalling.38  
 
Conclusion and Future Directions 
Taken together, these results reveal that the ribosome can synthesize peptides with two 
consecutive α-hydroxy-β-amino acids or two α-hydroxy-β-amino acids separated by a three α-amino acid 
spacer. In contrast, the ribosome is unable to efficiently synthesize pentapeptides with three α-hydroxy-β-
amino acids flanked by two α-amino acids or alternating α-hydroxy-β-amino acids with α-amino acids, as 
observed by the intermediate peptide accumulation. Intermediate peptide accumulation is consistent with 
ribosome stalling due to premature tRNA drop-off, a possible consequence of multiple α-hydroxy-β-amino 
acids adopting incompetent conformations within the PTC that are unable to enter subsequent elongation 
cycles. These findings offer a starting point for ways to improve the incorporation α-hydroxy-β-aminoacyl-
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4 Chapter 4 Materials and Methods 
Materials 
 
All the protocols described here were adapted from the protocols described in Dr. Phil Effraim’s dissertation, 
and Dr. Mike Englander’s and following Dr. Margaret Elvekrog’s dissertation.  
 
Tightly-coupled 70S ribosomes from MRE 600 cells were prepared as described.1 Initiations factors, and 
elongation factors were previously prepared by former Gonzalez Lab and Cornish Lab members.1 All tRNAs 
were purified from E. coli and purchased from Sigma Aldrich or MP Biomedicals (tRNAfMet, tRNAPhe, 
tRNALys) mRNA templates were obtained by run-off in vitro transcription using double-stranded, linear DNA 
encoding variants of bacteriophage T4 gene product 32 (T4gp32) and T7 RNA polymerase.1 All amino 
acids were purchased from ChemImpex. For the synthesis of di- and tripeptides, all the chemicals and 
solvents were purchased from Sigma Aldrich and used without further purification.  
 
Methods 
4.1.1 Enzymatic Aminoacylation of natural aa-tRNAs 
All the tRNAs used for these studies were purchased from Sigma Aldrich. The 35S-Met was purchased from 
Perkin Elmer.  MTHF was prepared following Dr. Margaret Elvekrog’s dissertation, section 5.1.1.1. 
4.1.1.1 fMet-tRNAfMet.  
125 mM Tris-HCl pH 7.5 at 37C, 35 mM MgCl2, 750 mM KCl, 0.5mM EDTA, 5 mM DTT was incubated with 
20 m M tRNA, 80 mM Met, 300 µM 10-FTHF, 2.5 mM ATP, 0.02 µM MetRS, and 0.2 µM  transformylase for 
10 min. 
4.1.1.2 35 S-fMet-tRNAfMet  
125 mM Tris-HCl pH 7.5 at 37C, 35 mM MgCl2, 750 mM KCl, 0.5mM EDTA, 5 mM DTT was incubated with 
20 m M tRNA, 4 m M Hot Met, 300 m M 10-FTHF, 2.5 mM ATP, 0.02 m M MetRS, and 0.2 µM  transformylase 
for 5 min. After 5 min, add 16 m M Met. Incubate for another 5 min.  
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4.1.1.3 Phe-tRNAPhe  
Mix15 m M tRNAPhe;Phe 55 mM; 200 mM TrisHCl pH 7.5; 15 mM MgCl; 25mM KCl, 2 mM BME; 5mM ATP; 
10 mM PEP; 30 µM  pyruvate kinase; 0.75 µM Phe aaRS. Incubate at 30C for 10min.  
 
4.1.1.4 Lys-tRNALys and Val-tRNAVal 
 50 mM TrisHCl pH=7.5; 7mM MgCl2; 150 mM KCl; 0.1mM EDTA; 1mM DTT; 20 µM tRNA; 2.5 mM ATP; 
80 mM amino acid; 1.1 µM  aaRS.  
 
All enzymatic natural aa-tRNA reactions were Phenol extracted two times and chloroform extracted once. 
0.1x volumes of 3M NaOac pH=5 were added along with 3x volumes of cold ethanol. Precipitate overnight 
in the -80C freezer. Spin at maximum speed for 30min at 4C. Wash pellet with 70% Ethanol. Resuspend 
the pellet and purify using P6 column. 
Efficiency for fMet-tRNAfMet and Phe-tRNAPhe: determine charging efficiency by FPLC using the cold 
reaction (Buffer A 1.7M Ammonium Chloride, 10mM Ammonium Acetate pH 6.3; Buffer B 10 mM 
Ammonium acetate pH 6.3, 10% MeOH). 
Efficiency for Lys-tRNALys and Val-tRNAVal: For efficiency calculations, set up a small scale reactions with 
32P-labeled tRNA.2 
4.1.2 Flexizyme Charging of Unnatural Amino Acids 
Flexizyme T7 Run-off Transcription was done according to published procedures. 3 
Flexizyme charging reactions. 20 µM tRNA; 600 mM MgCl2; 20 m M eFx or dFx; 100 mM Hepes-KOH; 5 
mM amino acid. To determine charging efficiency, follow 32P-labeling protocol to label tRNA, and run a the 
small scale reaction with 100 pmol of tRNA final.2 Incubate reaction mixture on ice until aminoacylation 







Time Course Summary of Flexizyme Charging Efficiencies onto tRNAPhe ** 
Unnatural Amino Acid Incubation Time at 0°C 
Isoserine** 2 hours 
α-hydroxy-β-Azide 6 hours 





**Conditions determined by Miguel Jimenez. 
Once ready to digest the hot reaction, incubate for 10 min at room temperature. Quench P1 digestion with 
15 μL of 200 mM NaOAc pH 5. Spot 0.25μL, 0.5μL, 0.75 μL, and 1 μL of the mixture on the TLC plate. Run 
the plate ¾ of the way.  
Work up cold reaction 
Quench with 0.1x reaction volume of 0.6M NaOAc pH 5. Add 3x reaction volume of 100% Ethanol. 
Precipitate for 3 hours or overnight. Pellet, wash with 70% Ethanol and resuspend with 20 uL of 10 mM 
KOAc pH 5. For the multiple incorporation experiments, minimum of 30 m M was necessary each aa-tRNA 
4.1.3 Translation Buffers 
Three different buffers were prepared for the translations. All buffers were filtered under steril conditions 
and aliquoted for single use.   
5x Polymix –Mg (250 M TrisOaA, pH=7.5; 500 mM KCl; 25 mM NH4OAc; 2.5 mM Ca(OAc)2; 25 mM 
putrescine; 5 mM spermidine; 30 mM BME; 5% glucose) 
5x Polymix + Mg (250 M TrisOaA, pH=7.5; 500 mM KCl; 25 mM NH4OAc; 2.5 mM Ca(OAc)2; 25 mM 
putrescine; 5 mM spermidine; 30 mM BME; 5% glucose, 15.35 mM Mg(OAc)2) 







4.1.4 Translation Reactions 
Final concentrations for translation components in (µM) 
Tightly coupled 70S ribosomes(0.5); IF1 (0.75); IF2 (0.75); IF3 (0.75); GTP (500); Mg2+ (3.5); 35S-fMet (.25); 
mRNA (3); EF-Tu (30); EF-TS (3); EF-G (1.5); aa-tRNAs (1 per incorporation) 
 
Initiation complexes 
Add ribosomes, initiation factors, GTP, polymix buffer +Mg, polymix buffer –Mg and water. Incubate at 37C 
for 10min. After the incubation period is over, add mRNA and water (if necessary). Incubate for 10min at 
37C. Then, add 35S-fMet-tRNAfMet and water and incubate at 37C for 10 min. Quickly spin down and keep 
at 0 C for at least 10min or until you are ready to assemble complexes.  
EF-G Complexes  
Mix 1.5 µM EF-G, 1 mM GTP, 3 μM phosphoenol-pyruvate, and 0.001 units/μL pyruvate kinase in polymix 
buffer +Mg buffer and store on ice until use. 
Pre-Ternary Complexes 
Mix 30 m M EF-Tu, 10 m M EF-Ts, GTP, pyruvakte kinase and PEP, Polymix buffer +Mg, Polymix Buffer –
Mg and Buffer 1x. Incubate at 1 min at 37C and 1 min on ice.  
Ternary Complex 
Assemble the necessary ternary complexes by adding 4.5 uL of preternary complex, required aa-tRNA(s), 
and water, if needed. Keep on ice until ready to use. 
Pre-Reaction Complex 
Mix 1.2 µL EF-G complex and 6.4 µL Initiation Complex. Keep on ice until ready to assemble translation 
reactions 
Assembling Translation Reactions 
Make sure all the tube contents are mixed well and spun down before starting the reaction. Incubate Pre-
Reaction Complex and Ternary Complex at 37C for 5m. Mix 6.4 µL ternary complex with Pre-reaction 
Complex fast as you start the timer. Incubate for 1h at 37C.  
Quenching the reactions 
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Quench 0.5 uL of rxn with 1 uL of 1M KOH. Mix well. Incubate at 37C for 5 min to make sure all radioactive 
species are released (this step minimized the origin). Then, spot 0.25 or 0.2 uL of the quenched reaction 
on the eTLC plate. Wait for the spots to dry. Wet the paper with running buffer without drenching the paper. 
If you drench the paper, your spots will not resolve. Use a long pipet to roll the buffer on the paper and roll 
the excess off the paper. Place the eTLC on the chamber and run at constant Volts for 30min. Take the 
plate out and let air dry 30-45min. Place the plate on the phosphorimager plate with saran wrap over it. 
Make sure that you don’t move the wrap once you have place the phosphorimager plate on the cover and 
close it. Leave overnight.  
Imaging the plate – Analysis: ImageQuant 
Draw circles around each spot of interest from top to bottom. Then, draw a large square in an empty area 
– this will be your background. When you report the volumes, delete all the columns except Volume and 
Area. Normalize the intensities obtained by eTLC and calculate yields: spot/(sum spots on the same 
lane)*100 = percent peptide. 
 
Authentic Marker Synthesis 
Synthesis of Fmoc-amino acids for Solid Phase Peptide Synthesis 
Dissolve 1 eq of amino acid in 5 mL water. Add 2 eq of NaHCO3. Cool to 0°C. Dissolve Fmoc-OSu in 5 mL 
dioxane. Add Fmoc-OSu solution dropwise to amino acid solution. Stir at room temperature for 16 hours. 
Extract with 20 mL of 1:1 ether : ethyl acetate. Wash the organic layer with saturated NaHCO3.  Combine 
the aqueous layers and acidify with 1M HCl to pH 3. Extract 3x with 20mL ethyl acetate. Wash organic 










Solid Phase Peptide Synthesis (SPPS) 
Fmoc-Lys (N-Boc) Resin Substitution: 
 0.43 mmol/g 
1 equivalent 0.1 g of resin  
(limiting factor) 0.04 mmol 
4 equivalents (uaa)** 0.17 mmol 
10 equivalents (for nat aa) 0.43 mmol 
9.9eq (for HCTU) 0.43 mmol 
20 eq for DIPEA 0.86 mmol 
*  Prepare 0.5M for amino acids 
 
Swell resin with 3 mL of dichloromethane. Deprotect resin for 30m with 3 mL of 20% piperidine in NMP. 
Wash resin with 5x5mL of NMP. Add the Fmoc-Phe, HCTU and DIPEA for the first coupling for 1 hour. 
Deprotect the resin with 3mL of 20% piperidine in NMP for 30m. Wash resin with 5x5mL of NMP. Couple 
fMet (add fMet, HCTU and DIPEA) for one hour. Wash resin with 5x5 mL NMP, 5x5 mL Methanol 5x5 mL 
Dichloromethane, and 5x5 mL diethyl ether. Keep under house vacuum for 10 min to remove any residual 
solvent.  To cleave resin, add 1 mL of 95% Trifluroroacetic Acid (TFA), 2.5% Triisopropyl Silane, 2.5% 
water. Stir for 4 hours. Note that sometimes solutions turn pink. After 4 hours, tightly plug a 1mL glass 
pipette with glass wool and filter off the resin. Add 15 mL of chilled diethyl ether (you will see a precipitate 
form). Centrifuge for 20min at 4°C. This will pellet the precipitated peptide. Decant Ether and purify by 
HPLC. 
Dipeptide Synthesis 
Boc-amino acid Synthesis 
Dissolve 1 eq of amino acid in 5 mL water. Add 3 eq of triethyl amine. Cool to 0°C. Dissolve Boc2O in 5 mL 
dioxane. Add Boc2O solution dropwise to amino acid solution. Stir at room temperature for 16 hours. Add 
1M NaOH to pH 10. Wash aqueous layer 2x with 20 mL ether. Discard organic layer. Acidify with 1M HCl 
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to pH 3. Extract aqueous later 3x with 20 mL ether and combine these organic layers, wash 1x 20 mL brine. 
Dry with sodium sulfate, decant and dry under reduced vacuum.  
Benzyl ester Boc amino acid Synthesis 
Under argon: Add 1.2 equivalents of Boc-amino acid, 1equivalent of benzyl bromide, 2 equivalents of 
anhydrous triethyl amine and 3 mL of anhydrous DMF and stir overnight at room temperature under argon. 
Dilute reaction with ether and wash 3x with 10 mL 0.5M HCl, 3x with 10mL saturated NaHCO3, and 1x 
20mL brine. Dry with sodium sulfate, decant and dry under reduced vacuum.  
TFA Deprotection Benzyl ester Boc amino acid 
To Benzyl ester Boc amino acid, add 5 mL dichloromethane. Cool to 0°C and add 5 mL TFA. Stir at 0°C for 
1 hour. Dry under vacuum and purify by flash column chromatography using a 0-15% methanol in 
dichloromethane gradient.   
Coupling fMet to Benzyl Ester amino acid 
Under argon, add 1 equivalent of fM, 1.2 equivalents of Benzyl ester amino acid, 1.1 equivalents of 
EDCHCl, 4.33 equivalents of DIPEA, and 3 mL DMF. Stir under argon at room temperature overnight. 
Remove DMF under reduced vacuum and purify by flash column chromatography using a 0-15% methanol 
in dichloromethane gradient. 
Deprotection fMet-amino acid benzyl ester 
Under Argon: To fMet-amino acid benzyl ester, add 0.1 equivalents of Pd/C, and 3 mL anhydrous Methanol. 
Then, add H2(g). Stir overnight under H2(g).Add Methanol and filter over celite to remove Pd/C and purify 










HPLC crude di- and tripeptides: monitor 220 nm 
Dissolve crude peptide in 5mL of water with 0.1% TFA and filter through 0.2 micron filter 
Peptide HPLC Purification Conditions 
fM-F 0%-40% Acetonitrile over 80min 
fM-F-K 0%-40% Acetonitrile over 80min 
fM-Iso 0%-40% Acetonitrile over 80min 
fM-Iso-K 0%-20% Acetonitrile over 40min 
fM-βPhe 0%-40% Acetonitrile over 80min 
fM-βPhe-K/fM- βPhe-R 0%-40% Acetonitrile over 80min 
fM-βLeu-K 0%-40% Acetonitrile over 80min 
fM-βPhe-βPhe-K 0%-50% Acetonitrile over 25min 
fM-βPhe-K-βPhe-K 0%-60% Acetonitrile over 30min 
fM-βPhe-βPhe-βPhe-K 0%-80% Acetonitrile over 40min 
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